<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867033</url>
  </required_header>
  <id_info>
    <org_study_id>ALTITUDES-1508</org_study_id>
    <nct_id>NCT02867033</nct_id>
  </id_info>
  <brief_title>National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES)</brief_title>
  <acronym>ALTITUDES</acronym>
  <official_title>National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ligue contre le cancer, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital de la Timone</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to constitute the French largest Aggressive fibromatosis cohort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aggressive fibromatosis (AF) is a rare non-metastasizing connective tissue tumor (&lt; 300
      cases/year in France), associated with high risk of local relapse, functional impairment and
      pain. AF can occur at any age, but most commonly between 25 and 40 with a significant female
      predominance. AF is most frequently (about 85%) sporadic and then associated with a somatic
      mutation of the CTNNB1 gene. AF is associated with heredity condition, as complication of
      familial adenomatous polyposis (with germinal mutation of Adenomatous polyposis coli (APC)
      gene). Most of AF arises on lims or abdominal wall. Nevertheless, some particular locations
      are life-threatening (mesenteric or cervical locations). The natural course of AF is
      unpredictable. One third of tumors are spontaneously stable. One third of tumor spontaneously
      decreases. One third of tumor is progressive, with a non-linear tumor growth dynamic. As the
      consequence the decision making for starting curative intent treatment is difficult, since
      some treatment could be mutilating (large en bloc surgery) or associated with late and severe
      complications (radiotherapy) and since these treatments could fail to control this benign
      tumor. Therapeutic options are: wait-and-see policy, surgery (sometimes mutilating),
      radiotherapy or systemic treatment (non-steroidal anti-inflammatory drugs, hormonotherapy,
      imatinib, chemotherapy). Level of evidence associated these options is very low, based on
      retrospective studies and rare non-randomized phase II clinical trials.

      Regarding these uncertainties, physicians can hardly answer to patient questions.

      Prospective data provided by a large multi-center cohort is needed. The objective of the
      present study is to create a large cohort of incident cases of AF associated with tumor bank
      and collection of blood samples.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incident cases of aggressive fibromatosis</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To constitute, at a national level, the largest cohort of incident cases of desmoid tumours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Aggressive Fibromatosis associated with familial adenomatous polyposis</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To describe and analyse the link between Aggressive Fibromatosis and familial adenomatous polyposis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CTNNB1 mutation in non-selected cases of Aggressive Fibromatosis</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To describe the proportion of AF cases characterized by CTNNB1 somatic mutation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment used for management of AF</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To describe the impact of different therapeutic strategies on AF recurrence and progression free survival, in homogenous risk level sub-groups of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>at baseline, one year</time_frame>
    <description>To describe the psychological impact of the disease at diagnosis and a year after diagnosis. And to compare changes between the time of diagnosis and one year after the treatments used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire (QLQC30)</measure>
    <time_frame>at baseline, one year</time_frame>
    <description>To describe the consequences of the disease on the quality of life at diagnosis and a year after diagnosis. And to compare changes between the time of diagnosis and one year after the treatments used.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mutation rate of APC</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To determine the mutation rate of APC at constitutional and somatic levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Mutation rate of CTNNB1</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To determine the mutation rate of CTNNB1 at constitutional and somatic levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation between APC and CTNNB1 mutations rates</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To demonstrate that APC and CTNNB1 mutations are two mutually exclusive molecular alterations</description>
  </other_outcome>
  <other_outcome>
    <measure>APC mutation rate</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To correlate mutational somatic and constitutional rate of APC gene</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of other mutations</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To search other molecular anomalies for patients without APC or CTNNB1 mutations (10 % of cases)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cell free (circulating) nucleic acid extraction technics</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To determine sensibility and specificity of cell free (circulating) nucleic acid extraction techniques</description>
  </other_outcome>
  <other_outcome>
    <measure>AF outcome</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To describe patient outcomes and identify prognostic factors</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment response</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To search for factors involved in response treatment prediction</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Aggressive Fibromatosis</condition>
  <arm_group>
    <arm_group_label>Study procedure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tumor biobank realization (biopsy...) and biobank constitution. coloscopy associated with colonic chromoscopy. Blood sampling (facultative). Pain evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>pre-therapeutic or post-therapeutic biopsy or resected tissues</description>
    <arm_group_label>Study procedure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biobank constitution</intervention_name>
    <description>Constitution of a biobank with pre-therapeutic or post-therapeutic biopsy or resected tissues</description>
    <arm_group_label>Study procedure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Coloscopy</intervention_name>
    <description>For adult patients, a coloscopy with chromoscopy of ascending and sigmoid colon will be performed</description>
    <arm_group_label>Study procedure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling (facultative)</intervention_name>
    <description>Blood sample can be collected at diagnostic or after medically significant events (progressive disease, local or systemic treatment, pregnancy...)</description>
    <arm_group_label>Study procedure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pain evaluation</intervention_name>
    <description>Pain evaluation (EVA scale), anxiety (HADS questionnaire), quality of life questionnaire (EORTC-QLQ-C30)</description>
    <arm_group_label>Study procedure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor biobank realization</intervention_name>
    <description>Realization of a tumor biobank is part of classical procedure of participating centers</description>
    <arm_group_label>Study procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Incident Case of aggressive fibromatosis in France

          -  Confirmed diagnosis by the French anatomopathological diagnosis network (including
             search for mutation of the β-Catenin Gene, CTNNB1)

          -  Affiliation to the National Health System

          -  Informed consent signed (both parents signature for non adult patients)

        Exclusion Criteria:

          -  Administrative or legal measure of liberty privation

          -  Patient not able to give consent or unwilling to provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Penel Nicolas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salas Sébastien, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Timone adultes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Decoupigny Emilie</last_name>
    <phone>+33 (0) 3 20 29 59 18</phone>
    <email>promotion@o-lambret.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Penel Nicolas, MD</last_name>
    <phone>+33 (0) 3 20 29 59 18</phone>
    <email>n-penel@o-lambret.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>PROUST Stéphanie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>BOMPAS Emmanuelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>lchaigneau@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>CHAIGNEAU Loïc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital des enfants</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>cecile.verite@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>VERITE Cécile, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ITALIANO Antoine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>DELCAMBRE Corinne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Caen-Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>minckes-o@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>MINCKES Odile, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jobay@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>BAY Jacques Olivier, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ISAMBERT Nicolas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble- Hôpital Couple Enfant</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>DPlantaz@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>PLANTAZ Dominique, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>PENEL Nicolas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>DEFACHELLES Anne-Sophie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>LERVAT Cyril, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>nadege.corradini@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>CORRADINI Nadège, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital la Timone Enfants Service Oncologie Pédiatrique</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ROME Angélique, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital la Timone Service Oncologie Médicale</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>DUFFAUD Florence, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>bertuccif@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>BERTUCCI François, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>didier.cupissol@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>CUPISSOL Didier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Mère Enfant - CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>sophie.dumoucel@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>RIGAUD Charlotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Archet 2</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>soler.c@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>SOLER Christine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>pascaline.boudou@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>BOUDOU- ROUQUETTE Pascaline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>thierry.andre@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>ANDRE Thierry, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>LEBBE Céleste, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpîtal Armand-Trousseau</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>PETIT A, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie Département Oncologie Médicale</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sophie.piperno-neumann@curie.fr</email>
    </contact>
    <investigator>
      <last_name>PIPERNO-NEUMANN Sophie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie Département Oncologie Pédiatrique</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>daniel.orbach@curie.fr</email>
    </contact>
    <investigator>
      <last_name>ORBACH Daniel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>PHUCHART C, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes- Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>alexis.arnaud@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>ARNAUD Alexis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUILLEMET Cécile, MD</last_name>
      <email>cecile.guillemet@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>GUILLEMET Cécile, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie-Hôpital René Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>laurence.bozec@curie.fr</email>
    </contact>
    <investigator>
      <last_name>BOZEC Laurence, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Site René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>BOMPAS Emmanuelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint Priest En Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>olivier.collard@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>COLLARD Olivier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>BERGER Claire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>KURTZ JE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>castex.mp@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>CASTEX Marie-Pierre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Régaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>CHEVREAU Christine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours - Clocheville</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>p.blouin@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>BLOUIN Pascale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Enfants- CHU Nancy</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>p.chastagner@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>CHASTAGNER Pascal, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>RIOS Maria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MIR Olivier, MD</last_name>
      <email>olivier.mir@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>MIR Olivier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>October 13, 2017</last_update_submitted>
  <last_update_submitted_qc>October 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>desmoid tumour</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aggression</mesh_term>
    <mesh_term>Fibroma</mesh_term>
    <mesh_term>Fibromatosis, Aggressive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

